Reveragen BioPharma, Inc.

Santhera Pharmaceuticals is set to hit the ground running with the launch of vamorolone now that regulators in Europe have recommended approval of the Swiss group's Duchenne muscular dystrophy (DMD)

With regulatory decisions imminent on both sides of the Atlantic for vamorolone, Santhera Pharmaceuticals has secured a North America partner for the closely watched Duchenne muscular dystrophy (DMD

New molecular entities had a rough week at the US FDA, as the agency issued a complete response letter for Gilead Sciences, Inc. ’s bulevirtide for hepatitis delta virus infection, CytoDyn, Inc. wi

Santhera Pharmaceuticals 's successful turnaround is continuing apace with its treatment for Duchenne muscular dystrophy (DMD), vamorolone, filed with regulators on both sides of the Atlantic but the